The Asia Pacific typhoid fever vaccines market is expected to reach US$ 135.79 million in 2027 from US$ 64.75 million in 2019. The market is estimated to grow with a CAGR of 10.0%from 2020-2027.
Key factors that are driving growth of the market are rising prevalence of typhoid, and increase in support for typhoid immunization. However, side-effects associated with typhoid fever vaccines hinder the Asia Pacific Typhoid Fever Vaccines market growth.
Typhoid fever is the most common bacterial infection among the Asian countries. Enteric fever is transmitted through contaminated food and water with human waste. Due to poor sanitation facilities in Asian countries, the prevalence of typhoid in Asian countries is high.
According to the recent estimates of the World Health Organization (WHO), typhoid is an endemic fever in Africa, Asia, Latin America, Oceania, and the Caribbean. The WHO also states that 80% of the typhoid fever cases arise from India, Bangladesh, China, Laos, Nepal, Indonesia, Vietnam, and Pakistan.
Furthermore, as per the study ‘Multidrug resistant enteric fever in South Asia: unmet medical needs and opportunities’ published in 2019, about seven million people are infected with typhoid each year in South Asia with around 75 000 deaths. As per the recent study by the All India Institute of Medical Sciences (AIIMS), around 494 per 100,000 children of age group 5–15 years suffered from typhoid in 2017.
Thus, the growing incidence of enteric fever (typhoid) in Asian countries is likely to drive the demand for typhoid vaccines in Asian countries during the forecast period.
Furthermore, Countries in the Asia Pacific are facing challenges due to increasing incidences of COVID-19. As per the data of Worldometer, as of counts as of October 06, 2020, China reported 85,482 COVID-19 cases, while in Japan, it stood at 85,739, India recorded 6,685,082 cases, and Australia reported 27,173 confirmed cases. In India, which reported a new daily high of 70,000 cases, nearly a dozen states have imposed a partial lockdown in high-risk areas. The outbreak has severely affected the tourism industry and imposed supply chain disruptions; moreover, low-income countries face additional challenges due to the shortage of healthcare infrastructure. Restrictive measures have been put forth in South Korea, Malaysia, Singapore, the Philippines, and India to prevent disease transmission.
Rest of Asia Pacific Typhoid Fever Vaccines Market Revenue and Forecast to 2027 (US$ Mn)

- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
Asia Pacific Typhoid Fever Vaccines – Market Segmentation
- Live Attenuated Vaccine
- Capsular Polysaccharide Vaccines
- Conjugate Vaccine
- Others
By Route of Administration
- Oral
- Injectable
By Country
- China
- Japan
- South Korea
- Australia
- India
- Rest of Asia Pacific
Company Profiles
- GlaxoSmithKline plc
- Shanghai institute of biological products co. Ltd.
- PT Bio Farma
- BIO-MED
- BHARAT BIOTECH
Asia Pacific Typhoid Fever Vaccines Report Scope
Report Attribute | Details |
---|---|
Market size in 2019 | US$ 64.75 Million |
Market Size by 2027 | US$ 135.79 Million |
Global CAGR (2020 - 2027) | 10.0% |
Historical Data | 2017-2018 |
Forecast period | 2020-2027 |
Segments Covered |
By Vaccine Type
|
Regions and Countries Covered | Asia-Pacific
|
Market leaders and key company profiles |
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Testimonials

I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.
DR CHIJIOKE ONYIA, MANAGING DIRECTOR, PineCrest Healthcare Ltd.
The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services
Yukihiko Adachi CEO, Deep Blue, LLC.Reason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Strategic Planning
- Investment Justification
- Identifying Emerging Markets
- Enhancing Marketing Strategies
- Boosting Operational Efficiency
- Tracking Industry Innovations
- Aligning with Regulatory Trends
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.















- GlaxoSmithKline plc
- Shanghai institute of biological products co., Ltd
- PT Bio Farma
- BIO-MED
- BHARAT BIOTECH


